Peter Rands, Chief Executive Officer, and Dr. Carol Routledge, Chief Medical and Scientific Officer, are presenting a webcast on the Company’s progress in the development of N,N-dimethyltryptamine (“DMT”) assisted therapy for the treatment of Major Depressive Disorder (“MDD”), which is available on-demand via the conference platform.
Small Pharma’s management team is also available for one-on-one in-person meetings on November 15 in London, England. To schedule a meeting, please contact LifeSci Advisors at eric@lifesciadvisors.com.